Review
Biochemistry & Molecular Biology
Lucia Haronikova, Ondrej Bonczek, Pavlina Zatloukalova, Filip Kokas-Zavadil, Martina Kucerikova, Philip J. Coates, Robin Fahraeus, Borivoj Vojtesek
Summary: This review discusses the mechanism of action, determinants of sensitivity, and resistance issues of MDM2 inhibitors, emphasizing the need for patient stratification based on these aspects to achieve better clinical responses.
CELLULAR & MOLECULAR BIOLOGY LETTERS
(2021)
Article
Biochemistry & Molecular Biology
Wei-Lun Chang, Chih-Hsiung Hsieh, I-Ying Kuo, Chien-Hsun Lin, Yu-Lin Huang, Yi-Ching Wang
Summary: A novel therapeutic agent, Nutlin-3, has been proposed to enhance the treatment efficacy of chemoradiation-resistant ESCC by regulating the expression of transcription factor proteins p53 and RB and downregulating the level of DNA methyltransferase. It has the potential for clinical application.
MOLECULAR CARCINOGENESIS
(2022)
Article
Oncology
Konstantina Psatha, Laxmikanth Kollipara, Elias Drakos, Elena Deligianni, Konstantinos Brintakis, Eustratios Patsouris, Albert Sickmann, George Z. Rassidakis, Michalis Aivaliotis
Summary: The activation of wild-type p53 protein in human lymphoma is a promising therapeutic strategy. An in vitro integrative comparative multi-omics analysis of different lymphoma types before and after p53 activation can shed light on the molecular mechanisms involved. Our findings provide valuable insights into the role of specific proteins and pathways in lymphoma pathogenesis and the global effect of nutlin-3a, which can guide targeted studies on lymphoma progression and resistance.
Article
Biochemistry & Molecular Biology
Maria Chiara Fontana, Jacopo Nanni, Andrea Ghelli Luserna di Rora, Elisabetta Petracci, Antonella Padella, Martina Ghetti, Anna Ferrari, Giovanni Marconi, Simona Soverini, Ilaria Iacobucci, Cristina Papayannidis, Antonio Curti, Ernesta Audisio, Maria Benedetta Giannini, Michela Rondoni, Francesco Lanza, Michele Cavo, Giovanni Martinelli, Giorgia Simonetti
Summary: In acute myeloid leukemia (AML), WIP1 inhibition proved to enhance the efficacy of MDM2 inhibitor Nutlin-3a in TP53-wt cases. Gene expression analyses showed increased p53, MDM2 and p21 levels in treated TP53-wt cells, while the drug combination synergistically reduced viability and induced apoptosis in TP53-wt AML cells. This study highlights the potential of targeting WIP1 to improve therapeutic outcomes in AML patients with wild-type TP53.
Article
Chemistry, Multidisciplinary
Shujie Li, Lian Li, Xi Lin, Cheng Chen, Chaohui Luo, Yuan Huang
Summary: This study focused on utilizing activated platelet-targeting nanoparticles to target the process of cancer metastasis, inhibiting tumor inflammation and tumor-platelet crosstalk simultaneously, resulting in a strong antimetastatic efficacy.
Article
Oncology
Irene Veneziani, Paola Infante, Elisa Ferretti, Ombretta Melaiu, Cecilia Battistelli, Valeria Lucarini, Mirco Compagnone, Carmine Nicoletti, Aurora Castellano, Stefania Petrini, Marzia Ognibene, Annalisa Pezzolo, Lucia Di Marcotullio, Roberto Bei, Lorenzo Moretta, Vito Pistoia, Doriana Fruci, Vincenzo Barnaba, Franco Locatelli, Loredana Cifaldi
Summary: The study demonstrated that Nutlin-3a could enhance NK cell-mediated killing of neuroblastoma cells by restoring p53 function and increasing ligand expression for NK-ARs. Adoptive transfer of human NK cells into neuroblastoma-bearing mice resulted in tumor shrinkage and improved overall survival. Nutlin-3a also boosted NK cell-mediated cytotoxicity against neuroblastoma spheroids by increasing ligand expression in primary neuroblastoma cells.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Chemistry, Multidisciplinary
Seok-Beom Yong, Srinivas Ramishetti, Meir Goldsmith, Yael Diesendruck, Inbal Hazan-Halevy, Sushmita Chatterjee, Gonna Somu Naidu, Assaf Ezra, Dan Peer
Summary: Chemo-immunotherapy is an advanced therapeutic modality for cancer treatment, but many patients still respond poorly to it. This study developed a dual targeted HO1-inhibiting lipid nanotherapeutic that sensitizes cancer cells to chemotherapy and improves the responsiveness to immune checkpoint inhibitor therapy by reprogramming tumor myeloid cells.
ADVANCED MATERIALS
(2022)
Review
Pharmacology & Pharmacy
Chao Tang, Heng Liu, Yanpeng Fan, Jiahao He, Fuqiu Li, Jin Wang, Yuchuan Hou
Summary: Bladder cancer is commonly treated with transurethral resection followed by intravesical chemotherapy, but conventional methods lack selectivity and efficiency. Nanomedicines offer targeted drug delivery with improved efficacy and precision, overcoming the challenges of conventional treatments.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Medicine, Research & Experimental
Charlie Marvalim, Arpita Datta, Soo Chin Lee
Summary: The transcription factor p53 plays a crucial role in regulating cellular processes and is activated in response to genotoxic stress. In breast cancer, p53's tumor suppressive activities are often compromised by the overexpression of MDM2 or mutation, with the latter being more common in hormone receptor-negative patients. Targeting both wild-type and mutant p53 in different subtypes of breast cancer has potential clinical relevance, and various therapeutic strategies including small molecule inhibitors, peptides, PROTACs, and genetic-based approaches are being developed. This review highlights the ongoing efforts to overcome p53 inactivation in breast tumors and discusses the efficacy and limitations of these therapeutic strategies.
Article
Oncology
Dasom Kim, Dongwha Min, Joohee Kim, Min Jung Kim, Yerim Seo, Byung Hwa Jung, Seung-Hae Kwon, Hyunju Ro, Seoee Lee, Jason K. Sa, Ji-Yun Lee
Summary: In this study, nutlin-3a, an MDM2 antagonist, was found to inhibit the KRAS-PI3K/Akt-mTOR pathway and disrupt the fusion of autophagosomes and macropinosomes with lysosomes. This led to a non-apoptotic and catastrophic macropinocytosis-like cell death, which was dependent on GFPT2 of the hexosamine biosynthetic pathway in KRAS mutant/p53 wild type NSCLC cells.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Review
Biochemistry & Molecular Biology
Neha Bhatia, Rakesh Khator, Swanand Kulkarni, Yogesh Singh, Pradeep Kumar, Suresh Thareja
Summary: The discovery of MDM2 and MDM2-p53 interaction inhibitors has revolutionized anticancer research due to their involvement in about 50% of cancer cases globally. In addition to inhibiting MDM2, targeting the interaction between MDM2 and p53 has proven to be an effective strategy for anticancer drug development. Both natural and synthetic molecules have shown promising MDM2 inhibitory potential. This review focuses on the pathophysiology of the MDM2-p53 interaction loop, characteristics of the active site, and the efficacy of various inhibitors from recent patents.
CURRENT MEDICINAL CHEMISTRY
(2023)
Article
Chemistry, Multidisciplinary
Jiangsheng Xu, James G. Shamul, Elyahb Allie Kwizera, Xiaoming He
Summary: Mitochondria are critical organelles for producing energy in cells and can be targeted for cancer therapy. Mitochondria-targeting nanotechnologies have shown high efficacy for cancer treatment both in vitro and in vivo, and can be intelligently designed based on the characteristics of the tumor microenvironment.
Article
Physics, Multidisciplinary
Han Zhou, Yi-Zhao Geng, Shi-Wei Yan
Summary: P53 is a tumor suppressor protein that regulates various cellular processes. It is negatively regulated by MDM2, which inhibits its activity. Inhibitors like Nutlin-3a can disrupt the interaction between p53 and MDM2, leading to the activation of p53 pathway and inhibition of tumor growth.
ACTA PHYSICA SINICA
(2023)
Article
Engineering, Biomedical
Yunjiang Zhou, Yaxin Chen, Yingying Tan, Rong Hu, Miao-Miao Niu
Summary: A potent anticancer D-peptide supramolecular nanomedicine targeting NRP1 and MDM2, named NMTP-5, with good biostability and strong anticancer activity has been identified for the treatment of liver cancer.
ADVANCED HEALTHCARE MATERIALS
(2021)
Article
Chemistry, Multidisciplinary
Vasanthan Ravichandran, Quan Truong Hoang, Thuy Giang Nguyen Cao, Min Suk Shim
Summary: This study developed biodegradable PLGA nanocapsules encapsulating oxygen-deficient MnWOx nanoparticles (NPs) and doxorubicin (DOX) for cancer-targeted chemo-sonodynamic combination therapy. The results showed that these nanocapsules could generate singlet oxygen and hydroxyl radicals upon ultrasound stimulation, leading to increased intracellular ROS levels and sonodynamic effects, thus exhibiting efficient cytotoxicity against cancer cells.
JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY
(2022)
Review
Biochemistry & Molecular Biology
Fahima Dilnawaz
CURRENT MEDICINAL CHEMISTRY
(2019)
Review
Oncology
Paromita Kundu, Deepika Singh, Abhalaxmi Singh, Sanjeeb K. Sahoo
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2020)
Editorial Material
Biotechnology & Applied Microbiology
Deepika Singh, Fahima Dilnawaz, Sanjeeb Kumar Sahoo
Article
Materials Science, Biomaterials
Abhalaxmi Singh, Sumeet Jain, Sanjeeb Kumar Sahoo
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
(2020)
Review
Pharmacology & Pharmacy
Priyanka Mohapatra, Priya Singh, Sanjeeb Kumar Sahoo
DRUG DISCOVERY TODAY
(2020)
Article
Biochemical Research Methods
Monalisa Mandal, Sanjeeb Kumar Sahoo, Priyadarsan Patra, Saurav Mallik, Zhongming Zhao
BMC BIOINFORMATICS
(2020)
Review
Biotechnology & Applied Microbiology
Priya Singh, Deepika Singh, Pratikshya Sa, Priyanka Mohapatra, Auromira Khuntia, Sanjeeb K Sahoo
Summary: The outbreak of SARS-CoV-2 infection has created an urgent need for advanced diagnostics and therapeutics, and nanotechnology appears to be highly relevant due to the unique properties of nanomaterials. This review discusses various nanoformulations that can be utilized in the fight against COVID-19, including personal protective equipment, disinfectants, diagnostics, therapeutics, and vaccination approaches utilizing nanoparticles to modulate the host immune system.
Article
Pharmacology & Pharmacy
Priya Singh, Sanjeeb Kumar Sahoo
Summary: Triple negative breast cancer (TNBC) exhibits higher rates of chemoresistance, metastasis, and relapse. This study explored the use of piperlongumine (PL) and PL-NPs to inhibit cancer stem cells (CSCs) in TNBC. Results showed that PL-NPs had higher cellular uptake in mammospheres and significantly inhibited various characteristics of CSCs. The downregulation of STAT3 was identified as a possible driving force behind these effects.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Article
Polymer Science
Rout George Kerry, Priyanka Mohapatra, Atala Bihari Jena, Bijayananda Panigrahi, Kahnu Charan Pradhan, Bibhu Ranjan Khatua, Subhasis Mahari, Satyanarayan Pal, Venkateswarlu Perikala, Bhagaban Kisan, Moses D. Lugos, Anil Kumar Mondru, Sanjeeb K. Sahoo, Dindyal Mandal, Sanatan Majhi, Jayanta Kumar Patra
Summary: Customized SiNPs were synthesized and successfully loaded with rutin trihydrate (RU), with various spectral analyses and in-silico studies revealing its promising antioxidant and anti-diabetic activities, as well as non-toxicity towards cells.
JOURNAL OF INORGANIC AND ORGANOMETALLIC POLYMERS AND MATERIALS
(2022)
Article
Toxicology
Deepika Singh, Priyanka Mohapatra, Sugandh Kumar, Somalisa Behera, Anshuman Dixit, Sanjeeb Kumar Sahoo
Summary: This study developed a strategy for targeting pancreatic Cancer Stem Cells (CSCs) by encapsulating a phytochemical Nimbolide in nanoparticles, inducing mesenchymal-to-epithelial transition. Molecular studies showed that Nimbolide binds to key regulator proteins of CSCs and negatively regulates their activity, ultimately leading to the transition of pancreatic CSCs.
TOXICOLOGY IN VITRO
(2022)
Review
Oncology
Sonali Sahoo, Priyanka Mohapatra, Sanjeeb Kumar Sahoo
Summary: Breast cancer is a global health issue for women, with current therapies having limited efficacy and adverse effects. Flavonoids have been found to have antitumor activity and can modulate various pathways in cancer. They also regulate cellular processes that prevent disease progression. A flavonoid-rich diet is considered a promising approach for cancer prevention. Natural products like flavonoids exhibit multi-target activities and may be a complementary therapy with fewer side effects than conventional chemotherapy. This review highlights the pharmacological effects of flavonoids on breast cancer and their specific mechanisms of action.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2023)
Review
Biochemistry & Molecular Biology
Pratikshya Sa, Sanjeeb K. Sahoo, Fahima Dilnawaz
Summary: Cancer is a major global health challenge, and the tumor microenvironment plays a vital role in tumor progression and drug resistance. Targeting the tumor microenvironment is a promising approach to advance cancer nanomedicine. Recent progress in understanding the tumor microenvironment and developing responsive nanoparticles has improved pharmacokinetics and efficacy of nanomedicine in overcoming drug resistance. This review discusses the components of the tumor microenvironment and the role of nanomedicine in combating drug resistance.
CURRENT MEDICINAL CHEMISTRY
(2023)
Review
Biochemistry & Molecular Biology
Fahima Dilnawaz, Sarbari Acharya
Summary: Genome editing has emerged as a promising approach for treating complex diseases such as cancer. Delivery technologies utilizing viral vectors have shown some success in protein and nucleic acid delivery, but improvements are still needed in terms of efficiency, tissue targeting abilities, and toxicity. Nanotechnology offers a potential solution by providing nano-vehicles that can overcome these challenges and serve as safe and efficient genome editing tools for cancer therapy.
CURRENT MEDICINAL CHEMISTRY
(2023)
Article
Nanoscience & Nanotechnology
Deepika Singh, Priya Singh, Arpan Pradhan, Rohit Srivastava, Sanjeeb Kumar Sahoo
Summary: This study presents a novel strategy for breast cancer therapy by co-delivering forskolin and paclitaxel in liquid crystal nanoparticles, effectively targeting both cancer stem-like cells and bulk tumor cells, which enhances treatment efficacy.
ACS APPLIED BIO MATERIALS
(2021)